Introduction
This article reviews important publications in the field of coeliac disease published between January 2006 and July 2007. It concentrates on developments in screening, diagnosis, pathogenesis and therapy.
Screening
Coeliac disease is common but it can be difficult to detect based on clinical symptoms alone. Early intervention can modify disease progress, and this makes coeliac disease a good candidate for screening. Screening can be targeted (i.e. aimed at high-risk groups) or nontargeted (population screening). Since 1997 serological [endomysial antibody (EMA) and anti-tissue transglutaminase (anti-tTG)] screening has been offered to all first-degree and second-degree relatives of patients with coeliac disease in south east Wales [1 ] . Patients diagnosed with coeliac disease by relative screening (n ¼ 32) were younger than those diagnosed routinely (median age 33 years versus 54 years) and suffered less from osteoporosis (9% versus 22%), anaemia (13% versus 58%) and other complications at diagnosis. This may reflect the fact that more were diagnosed at an earlier stage of coeliac disease development. In a US-based screening of 171 family members (88% were first-degree relatives and 12% were seconddegree relatives) who had previously had a negative EMA [2] , six subsequently seroconverted [3 ] . The mean time to seroconversion was 1.7 years (range 0.5-3.17 years). One-time screening may therefore be insufficient to detect all those who will develop coeliac disease, although this was a high-risk group.
Another study of first-degree relatives was conducted to evaluate the usefulness of human leucocyte antigen (HLA)-DQ2 genotyping [4 ] . HLA serology in 221 firstdegree relatives of 82 DQ2-positive coeliac disease patients was assessed, and duodenal biopsies for histological examination were taken in those who were DQ2 positive. Biochemical parameters and bone mineral density were recorded. A total of 130 relatives (58.8%) were DQ2 positive, with 64 of these (49.2%) having Marsh 0 (i.e. 'normal') lesions, 32 (24.6%) Marsh I [i.e. increased intraepithelial lymphocytes (IELs) only], one (0.8%) Marsh II, and 13 (10.0%) Marsh III; 20 individuals (15.4%) refused to undergo biopsy. Relatives with Marsh I lesions were more often symptomatic (56.3%) and anaemic (21.4%) than were those with Marsh 0 lesions (21.1% and 6.2%, respectively). The prevalence of abnormal bone mineral density was similar between those relatives with Marsh I lesions (37%) and Marsh III lesions (44.4%). The authors concluded that villous atrophy is not necessary to recommend a gluten-free diet (GFD), at least in DQ2-positive relatives of coeliac disease patients. Bourgey et al.
[5 ] evaluated the HLA-related genetic risk that future siblings of children with coeliac disease will also develop coeliac disease. In a cohort of 188 Italian families, in which at least one sibling and both parents were tested, the overall risk for a sibling to develop coeliac disease was approximately 10% (range 0.1-29%).
A clinical decision tool that uses pre-endoscopy serological testing and assessment of symptoms in patients attending for gastroscopy was devised and assessed by Hopper et al. [6 ]. An initial retrospective cohort of 1464 unselected patients who underwent duodenal biopsy was used to design the tool. 
Diagnosis
The 'gold standard' for diagnosis remains histology, although for screening purposes serology is used.
Serology
The best way to test for coeliac disease serologically remains controversial, with no defined standard regarding the use of EMA, tTG and AGA. Reeves et al.
[8 ] used a multicentre approach to define the optimal screening for coeliac disease, considering whether IgA-tTG AE IgG-tTG could be used as a replacement for EMA. Dual-isotype (i.e. use of more than one type of kit) transglutaminase (tTG-dual), combined-isotype transglutaminase (IgAtTG þ IgG-tTG), IgA-tTG, combined-isotype AGA (IgA-AGA þ IgG-AGA), IgA-AGA, and EMA assays were compared. The cohort included 254 patients but 228 were 'biopsy negative', which calls into question whether these patients did indeed have coeliac disease. The protocol tested for IgA-tTG, followed by IgG-tTG if negative. IgG-tTG increased diagnostic sensitivity for coeliac disease in IgA-deficient individuals with a sensitivity of 100% for dual-isotype tTG versus 66.67% for IgA-tTG. For the 10.6% of individuals with reduced IgA levels, the dual or combined isotype-tTG testing approach was superior to either isotype measurement in isolation. Total IgA measurement did not provide enhanced diagnostic sensitivity when dual-isotype tTG testing was employed. Serological assessment of coeliac disease with tTG screening (IgA AE IgG isotype) was concluded to be an alternative to EMA. This study also confirms that AGA antibody testing no longer appears to be a part of the diagnostic strategy.
Sinclair et al. [9 ] sought an easier and more cost-effective way to exclude IgA deficiency without measuring total serum IgA. Optical density readings on enzyme-linked immunosorbent assays of 608 routine samples received for tTG antibody testing for coeliac disease were compared with total IgA concentrations. A linear correlation between optical density values and levels of serum IgA was seen, such that the latter only needed to be tested for its absence if the optical density was under 0.050 on enzyme-linked immunosorbent assay. Then, if total IgA is within the agerelated reference range, the negative tTG antibody can be reported.
Another possible use of serological markers is to predict severity of mucosal damage. IgA antiactin antibodies (IgA-AAA) are circulating autoantibodies directed toward the intracellular cytoskeleton actin filaments [10,11]. Carroccio et al.
[12 ] reported a four centre study conducted to evaluate their potential role in monitoring intestinal mucosal lesions. The study included 205 patients with newly diagnosed coeliac disease with villous atrophy, 80 healthy control individuals and 81 disease control individuals. Serum IgA-AAA values were significantly higher in patients with coeliac disease than in healthy or disease control individuals (P < 0.0001). The serum levels were positive in 41 of the 60 coeliac disease patients with mild intestinal histological lesions (69%) and in 123 of the 145 with severe lesions (85.3%; P < 0.05). Serum IgA-AAA expression correlated (P < 0.0001) with the severity of intestinal damage, even in those on a self-reported GFD.
Levels of soluble CD163, a scavenger receptor [13] shed by tissue macrophages, have been shown to be higher in patients with untreated coeliac disease than in those with treated disease and to correlate with severity of the coeliac lesion, as classified according to the Marsh criteria [14 ] . Similarly, expression of matrix metalloproteinases (MMPs), which belong to a family of neutral proteases that are capable of degrading extracellular matrix and basement membrane components, were recently examined in duodenal biopsies of 30 patients with coeliac disease [15] . There was increased expression of this family of proteases in coeliac disease and high correlation with mucosal damage. The authors hypothesized that MMPs may have an additional, as yet unidentified role within the innate immune system and development of coeliac disease, as well as its usual degradation role, supporting earlier work [16, 17] .
Histology
Difficulty often arises when a patient who is suspected of having coeliac disease has a negative EMA result with a borderline histology. In 883 patients who underwent upper gastrointestinal endoscopy at Tampere University Hospital, Finland between 1995 and 2000 and in whom small bowel biopsy was performed when coeliac disease was suspected, regardless of antibody result, villous atrophy and crypt hyperplasia were found in 177 (21%) patients [18 ] . The clinical and histological features of IgA-competent, EMA-negative coeliac disease patients were compared with those in EMA-positive patients; the investigators also determined whether tTG-specific IgA deposits could be found in small bowel mucosa, even in the patients with seronegative tTG coeliac disease. Of those with coeliac disease, 26 (15%) had negative serum EMA, of which four were IgA deficient. The presence or otherwise of tTG-specific IgA deposits in the small bowel mucosa could help in cases with ambiguous histology, but the lack of a gold standard in these cases makes interpretation difficult.
Pathogenesis
Numerous factors are important in the development of coeliac disease, and these are discussed below.
Human leucocyte antigen factors
Jores et al. [19] identified a clear-cut correlation between those homozygous for the HLA-DQB1Ã0201 allele and the extent of intestinal damage, but not the clinical presentation.
Non-human leucocyte antigen factors
Rho-GTPase proteins such as myosin IXB (encoded by MY09B) are known to play a role in epithelial cytoskeletal organization. MYO9B polymorphisms have been identified as a predisposing factor for coeliac disease in analyses conducted by different European groups [20] [21] [22] . Recent data suggest that variation in MYO9B gene polymorphisms does not appear to have a major effect on coeliac disease in the UK [23 ] and South Italian [24 ] populations. Other genetic associations recently considered include the SPINK (serine protease inhibitors of the Kazal type) genes, which play a role in tissue preservation through the containment of uncontrolled proteolysis and bacterial growth. In the Dutch population evaluated by Wapenaar et al.
[25 ] no risk linkage was identified, in contrast to previous work.
In a large multicentre study, van Heel et al. [26] conducted a genome-wide association study for coeliac disease and identified risk variants in the interleukin (IL)-2/ IL-21 region of chromosome 4. ], using two-dimensional difference gel electrophoresis, investigated the proteins associated with an aberrant T-cell population in refractory coeliac disease. Significantly higher levels of IgM, apolipoprotein C-III (which is an inhibitor of lipoprotein lipase) and CharcotLeyden crystal proteins (eosinophil-specific granule protein) were demonstrated in a duodenal biopsy specimen of the patient with refractory coeliac disease compared with biopsies from four patients with coeliac disease.
The pathology of coeliac disease is associated with an expansion of IELs, both ab and gd, in the damaged mucosa. Kolkowski et al. [28] presented a report on the cytokine profile of CD8 þ ab IELs as compared with clones derived from noncoeliac disease donors. An imbalance in the production of IL-10 and IL-2 was observed. Coeliac disease clones capable of high toxicity produced IL-2, whereas most cytotoxic noncoeliac disease IELs produced IL-10. This finding may also be significant, given the low generation of regulatory CD8
þ IELs (that produce IL-10) seen in coeliac disease. Such work suggests that the imbalance between functionally distinct IEL populations resident in the small bowel may be involved in the pathogenesis of coeliac disease, primarily through the decrease in IL-10 producing IELs.
It has become increasingly recognized that natural killer cells have an important role to play as immunoregulatory cells in the pathogenesis of a number of autoimmune conditions such as type I diabetes mellitus [29] and systemic sclerosis [30] . Grose et al. [31] investigated whether a deficiency in number and function of invariant natural killer cells (which produce IL-4 and interferon-g, and hence suppress the T-helper-1 response) was present in coeliac disease. They found that patients with coeliac disease were deficient in invariant natural killer cells, which were functionally defective in producing IL-4. This could allow a T-helper-1 rather than a T-helper-2 immune response to contribute to the inappropriate activation of gluten-sensitized T cells.
A tumour necrosis factor-a-308 polymorphism ( À308 A) variant, which consists of a guanine to adenine transition, has been associated with enhanced tumour necrosis factor-a production. Data were collected on the frequency of this polymorphism in children with coeliac disease and type I diabetes mellitus, and of a similar transition at position 238 ( À238 A), although the exact effect of this on tumour necrosis factor-a production (if any) is as yet unknown [32] .
À238 A is known to be associated with increased severity of several autoimmune diseases. There was no evidence that the À308 A carrier state conferred additional risk for coeliac disease in type I diabetes mellitus. There was, however, a significantly higher rate of À238 A in the histology-proven coeliac disease group than in a noncoeliac disease group with type I diabetes mellitus.
There is growing evidence for a role in coeliac disease pathogenesis for IL-15 [33, 34] , which has multiple functions at the interface between innate and adaptive immunity. Benahmed et al. [35 ] demonstrated that IL-15 is markedly over-expressed in the mucosa of patients with active coeliac disease. This observation is consistent with the finding that transforming growth factor-b signalling in mucosal T cells is impaired by the heightened expression of IL-15, leading to sustained intestinal inflammation and injury [36 ] .
Another cytokine that has raised interest is macrophage migration inhibiting factor, a peptide that is expressed by various cells, such as monocytes/macrophages and eosinophils. Nunez et al.
[37 ] studied the frequency, in 531 Spanish patients with coeliac disease, of their chosen migration inhibiting factor susceptibility marker (a [CAAR] 5-8 tetranucleotide repeat at position -794), which has strong linkage disequilibrium with a transition at position -173 of guanine to cytosine. Their work suggested that this haplotype, which is associated with several other autoimmune diseases, significantly increases the risk for coeliac disease (odds ratio ¼ 1.32).
Other predisposing candidates for coeliac disease
The intercellular adhesion molecule-1 gene is a good candidate for coeliac disease predisposition because its encoded protein acts as an adhesion and co-stimulatory receptor for transendothelial migration of neutrophils to inflammatory sites. Abel et al.
[38 ] investigated the contribution of intercellular adhesion molecule-1 to coeliac disease risk by analysing the frequency of two frequent single nucleotide polymorphisms. One single nucleotide polymorphism, resulting in a change at position 241 of glycine to arginine, predisposed to adulthood-onset coeliac disease in French Caucasian patients (odds ratio ¼ 4.2). Unfortunately, the functional consequences of this frequent polymorphism are not known.
Treatment
GFD remains the only available therapy for coeliac disease. Alternatives are being actively investigated.
Gluten-free diet
Gluten-free products are not always widely available and are usually more expensive than their gluten-containing counterparts. This problem has been highlighted again [39] , as has the diversity in gluten product consumption and labelling standards across the European Union (currently, this can vary from 20 to 200 parts per million). Based on the need to establish a safe pan-European Union threshold, Catassi et al. [40 ] aimed to establish the safety threshold of prolonged exposure to trace amounts of contaminating gluten. They conducted a multicentre (albeit all Italian), double-blind, placebo-controlled randomized trial in 49 adults with biopsy-proven coeliac disease who were on a GFD. Abnormal intestinal morphology persisted in a significant proportion of coeliac disease patients being treated with a GFD, possibly due to the persisting ingestion of hidden gluten. An intake of 50 mg gluten per day produced significant mucosal damage, suggesting that gluten should be kept to lower levels than this when treating coeliac disease.
An alternative treatment strategy is to 'neutralise' gluten once it has been ingested. A decapeptide derived from durum wheat (10mer sequence QQPQDAVQPF) was recently shown to inhibit the lymphocyte response to gliadin peptides [41 ] , suggesting that potentially new therapeutic approaches to coeliac disease may be found in naturally occurring toxic cereals.
Enzymatic degradation
In the search for new treatments to help reduce the impact that following a GFD has on a patient's lifestyle, two recent studies from the same group in Amsterdam [42 ,43] were conducted to determine the efficiency of gluten degradation by a postproline cutting enzyme, namely prolyl endoprotease from Aspergillus niger. The authors showed that prolyl endoprotease from A. niger can act under conditions similar to those found in the gastrointestinal tract and is capable of degrading intact gluten molecules and T-cell-stimulatory epitopes from gluten into harmless fractions. Work by Garcia-Horsman et al.
[44], however, appeared to rule out any significant role in coeliac disease, because they found that prolyl endoprotease was unable to eliminate the gliadin-derived immunoactive and toxic peptides larger than 33mer. They did comment that because of the lack of an animal model, the in-vivo efficacy would have to be ultimately addressed in clinical studies involving coeliac disease patients.
Conclusion
Although much research is still focused, quite rightly, on pathogenesis of and susceptibility to coeliac disease, little progress appears to have been made in the treatment of coeliac disease over and above the use of a GFD, but even this strategy is compromised by differing international standards. More research into the use of biotechnologies that decrease the risk for gluten contamination in both 'gluten free' products and 'normal' foods is desirable. In the interim, however, efforts to improve the accuracy of coeliac disease diagnosis must continue, both to inform those with unknown coeliac disease of the potential consequences and to limit the number of patients who may be diagnosed with this condition in error.
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